Overexpression of HER-2 in thick melanoma

被引:13
作者
Eliopoulos, P
Mohammed, MQ
Henry, K
Retsas, S
机构
[1] Charing Cross Hosp, Hammersmith Hosp NHS Trust, Melanoma Unit, Directorate Canc Serv & Haematol, London W6 8RF, England
[2] Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Histopathol, Charing Cross Hosp, London W6 8RF, England
关键词
HER-2; malignant melanoma; overexpression; prognosis;
D O I
10.1097/00008390-200204000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study we evaluated the overexpression status of HER-2 and its prognostic significance on survival In patients with thick cutaneous malignant melanoma. The immuno-alkaline phosphatase antigen detection technique was applied to archival diagnostic material from 51 patients with primary lesions measuring greater than or equal to 10 mm in Breslow thickness. Eleven additional patients with primary lesions measuring less than or equal to 1 mm were also studied. HER-2 overexpression was evaluated using conventional light microscopy and an automated cellular imaging system (Chromavision Medical System). Fifteen (29.4%) out of 51 patients with thick lesions showed HER-2 overexpression. In contrast, no overexpression was seen in any of the thin lesions. Overexpression of HER-2 In this group of patients was of no prognostic significance for freedom from recurrence or survival when studied using univariate and multivariate analyses. Whilst the Incidence of HER-2 overexpression in patients with thick cutaneous primary melanoma Is similar to that reported in breast cancer, it was of no prognostic significance for survival In this study. However, further evaluation in larger numbers of patients with the full spectrum of Breslow thickness is clearly indicated. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 50 条
[11]   Individualized prognosis for melanoma patients [J].
Cochran, AJ ;
Elashoff, D ;
Morton, DL ;
Elashoff, R .
HUMAN PATHOLOGY, 2000, 31 (03) :327-331
[12]   Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy [J].
Einzig, AI ;
Schuchter, LM ;
Recio, A ;
Coatsworth, S ;
Rodriquez, R ;
Wiernik, PH .
MEDICAL ONCOLOGY, 1996, 13 (02) :111-117
[13]   PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].
GUSTERSON, BA ;
GELBER, RD ;
GOLDHIRSCH, A ;
PRICE, KN ;
SAVESODERBORGH, J ;
ANBAZHAGAN, R ;
STYLES, J ;
RUDENSTAM, CM ;
GOLOUH, R ;
REED, R ;
MARTINEZTELLO, F ;
TILTMAN, A ;
TORHORST, J ;
GRIGOLATO, P ;
BETTELHEIM, R ;
NEVILLE, AM ;
BURKI, K ;
CASTIGLIONE, M ;
COLLINS, J ;
LINDTNER, J ;
SENN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056
[14]   THE BIOLOGY OF ERBB-2 NEU HER-2 AND ITS ROLE IN CANCER [J].
HYNES, NE ;
STERN, DF .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (2-3) :165-184
[15]   Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma [J].
Karjalainen, JM ;
Eskelinen, MJ ;
Nordling, S ;
Lipponen, PK ;
Alhava, EM ;
Kosma, VM .
BRITISH JOURNAL OF CANCER, 1998, 77 (11) :1917-1925
[16]  
KERN JA, 1990, CANCER RES, V50, P5184
[17]   Overexpression of HER2/neu in solid tumours: an immunohistochemical survey [J].
Koeppen, HKW ;
Wright, BD ;
Burt, AD ;
Quirke, P ;
McNicol, AM ;
Dybdal, NO ;
Sliwkowski, MX ;
Hillan, KJ .
HISTOPATHOLOGY, 2001, 38 (02) :96-104
[18]  
KOPF AW, 1987, CANCER, V59, P1236, DOI 10.1002/1097-0142(19870315)59:6<1236::AID-CNCR2820590634>3.0.CO
[19]  
2-I
[20]  
LIN JT, 1995, CANCER RES, V55, P1428